+8.9%
CRCL vs GSK
+22.8%
-14.0%
-80.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.3% | 0.0% | +0.3% | +0.3% |
| 7D | -11.2% | -3.5% | -7.7% | -12.4% |
| 30D | +27.1% | -3.4% | +30.6% | +25.5% |
| 3M | +9.6% | -8.1% | +17.8% | +6.1% |
| 6M | -19.7% | -11.1% | -8.6% | -22.4% |
| YTD | +14.2% | +0.7% | +13.5% | +18.2% |
| 1Y | -32.2% | +20.1% | -52.4% | -22.6% |
| All | +8.9% | +22.8% | -14.0% | +5.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling